Esperion Therapeutics stock (US2964331002): Archimed acquisition deal closes chapter on independent biotech

Esperion agreed to be acquired by Archimed for up to $1.1 billion on May 1, 2026, with shareholders receiving $3.16 per share plus potential milestone payments tied to future drug sales.

Esperion Therapeutics announced a definitive acquisition agreement with Archimed, a healthcare-focused investment firm, on May 1, 2026, marking a significant milestone for the independent cardiovascular biotech company. Under the deal, Esperion shareholders will receive $3.16 per share in cash at closing, representing a 58% premium to the stock's closing price on April 30, 2026, according to Zacks as of May 1, 2026. The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions.

As of: May 14, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Esperion Therapeutics Inc.
• Sector/industry: Biopharmaceuticals – cardiovascular therapeutics
• Headquarters/country: United States
• Core markets: United States, cardiovascular disease management
• Key revenue drivers: Nexletol and Nexlizet (bempedoic acid-based therapies), Enbumyst (bumetanide-based product)
• Home exchange/listing venue: Nasdaq (ESPR)
• Trading currency: USD

Esperion Therapeutics: core business model

Esperion develops and commercializes oral, once-daily non-statin therapies targeting patients with elevated low-density lipoprotein cholesterol (LDL-C) who struggle to maintain healthy levels through conventional treatments. The company's lead products, Nexletol and Nexlizet, represent a differentiated approach to cardiovascular risk reduction in a market dominated by statins and PCSK9 inhibitors. Esperion's portfolio also includes Enbumyst, a bumetanide-based product addressing additional cardiovascular indications.

Acquisition structure and milestone payments

Beyond the $3.16 per share upfront payment, Esperion shareholders are entitled to receive contingent milestone payments of up to $100 million tied to future U.S. commercial performance. The first milestone of up to $40 million is contingent on U.S. net sales of bempedoic acid-based therapies reaching specified thresholds in 2027, while a second $60 million payment depends on annual U.S. net sales of bumetanide-based products meeting targets by the end of 2030, according to Zacks as of May 1, 2026. This structure aligns Archimed's acquisition with Esperion's ability to drive commercial adoption of its therapies.

Market reaction and stock performance

Esperion shares surged approximately 44% over the month following the acquisition announcement, reflecting investor enthusiasm for the deal premium and the validation of the company's therapeutic approach. The stock traded near $3.12 on May 13, 2026, according to market data. Upon completion of the transaction, Esperion will become a privately held company and will no longer trade on the Nasdaq.

Recent financial performance

Esperion reported Q1 2026 earnings on May 8, 2026, posting an EPS of -$0.10, which missed analyst consensus of -$0.02 by $0.08. Quarterly revenue reached $80.10 million, below the consensus estimate of $84.52 million, according to MarketBeat as of May 8, 2026. The company's trailing EPS stood at -$0.17, though analysts projected 340% earnings growth for the following year.

Conclusion

The Archimed acquisition represents a strategic exit for Esperion shareholders, providing immediate liquidity at a substantial premium while preserving upside exposure through milestone payments tied to commercial execution. For U.S. investors who held the stock, the deal offers clarity on valuation and a defined path to liquidity. The transaction underscores continued investor interest in differentiated cardiovascular therapeutics, even as the biotech sector navigates pricing pressures and competitive dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.